Dolutegravir Combo Beats Atripla in Head-to-Head Trial
Shionogi-ViiV Healthcare LLC's HIV drug dolutegravir beat Gilead Sciences Inc.'s Atripla in a Phase III trial in treatment-naive adults with HIV-1 infection. Initial results showed that 88 percent of patients receiving dolutegravir with Kivexa/Epzicom (abacavir/lamivudine) were virologically suppressed, compared to 81 percent on Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate).
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST